Evaluation of Rosuvastatin Solution in Post-Extraction Alveolar Bone Repair: An In Vivo Research Study
Authors:
- Tiago QueirozTiago Queiroz
- Vittorio MoraschiniVittorio Moraschini
- Suelen Cristina SartorettoSuelen Cristina Sartoretto
- Adriana Terezinha Neves Novellino AlvesAdriana Terezinha Neves Novellino Alves
- Rodrigo Figueiredo de Brito ResendeRodrigo Figueiredo de Brito Resende
- Marcelo UzedaMarcelo Uzeda
- Kayvon JavidKayvon Javid
- Ilia DeylamiIlia Deylami
- Monica Diuana Calasans-MaiaMonica Diuana Calasans-Maia
- Carlos Fernando MourãoCarlos Fernando Mourão
- Rafael Seabra LouroRafael Seabra Louro
Open Access
- 13 March 2024
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 14 (6) , 2415
Abstract
Statins have demonstrated positive results in alveolar repair after induced osteoporosis in humans and rats. This study aimed to evaluate the osteogenic potential of rosuvastatin (RSV) solution associated with collagen sponge in post-extraction rat alveoli. An experimental study was carried out at the Fluminense Federal University in 30 Wistar rats (female) randomly distributed into three experimental groups: group I—dental sockets filled with a blood clot (CS); group II—dental sockets filled with collagen sponge (EC); and group III—collagen sponge associated with RSV. Slides stained with hematoxylin and eosin (HE) were used for histomorphometric analysis to evaluate newly formed bone, connective tissue, and biomaterial in the respective groups, comparing them over different periods (7 and 42 days). The Shapiro–Wilk test was used to evaluate the same experimental period, and the Mann–Whitney test was used to compare the different periods between the groups. At 7 days, the clot group showed greater new bone formation (median 23.27; IQR 10.62–4.74) than the sponge group (median 2.25; IQR 3.42–1.53) and RSV group (median 0; IQR 0–0; p = 0.03), respectively. At 42 days, the clot group (median 63.90; IQR 7.54–3.73) showed better results regarding newly formed bone compared to the RSV group (median 26.33; IQR 4.78–2.24; p = 0.003). The present study demonstrated no advantages in the use of RSV in relation to the control group and no statistical difference between groups II and III.Keywords
This publication has 30 references indexed in Scilit:
- Comparative evaluation of subgingivally delivered 1.2% rosuvastatin and 1% metformin gel in treatment of intrabony defects in chronic periodontitis: A randomized controlled clinical trialJournal of Periodontology, 2018
- Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cellsJoint Bone Spine, 2013
- No Effect of Rosuvastatin in the Zoledronate-Induced Acute-Phase ResponseCalcified Tissue International, 2011
- In vivo performance of absorbable collagen sponges with rosuvastatin in critical-size cortical bone defectsActa Biomaterialia, 2010
- Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG‐63 culturesJournal of Cellular Biochemistry, 2007
- Atorvastatin stimulates the production of osteoprotegerin by human osteoblastsJournal of Cellular Biochemistry, 2005
- Induction of osteoblast differentiation indices by statins in MC3T3‐E1 cellsJournal of Cellular Biochemistry, 2004
- Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cellsBiochemical and Biophysical Research Communications, 2003
- Carbonate substitution in precipitated hydroxyapatite: An investigation into the effects of reaction temperature and bicarbonate ion concentrationJournal of Biomedical Materials Research, 1998
- Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitorsTrends in Pharmacological Sciences, 1998